Squarepoint’s Spruce Biosciences SPRB Stock Holding History

Squarepoint’s Portfolio SPRB Stock Details SPRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-181	Closed	-$61K	–	3653
2021 Q4	$61K	Buy	+181	New	+$53.9K	﹤0.01%	3001

Other funds holding SPRB

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Squarepoint's SPRB Position: Q1 2022 in Review

Squarepoint sold out of Spruce Biosciences (SPRB) in Q1 2022, closing a stake of 181 shares — an estimated $61K sold.

Squarepoint first reported a position in SPRB in Q4 2021 and held it in 1 quarter. The position peaked at $61K in Q4 2021. 43 funds tracked by Wall St. Rank hold SPRB as of Q1 2022.

Squarepoint reported no remaining Spruce Biosciences position as of Q1 2022 after selling out during the quarter.
Squarepoint sold 181 Spruce Biosciences shares in Q1 2022, an estimated $61K.
Squarepoint first reported a position in Spruce Biosciences in Q4 2021 and held it in 1 quarter.
Squarepoint's Spruce Biosciences position peaked at $61K in Q4 2021.
43 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.